In advanced stage ovarian cancer patients 20-30% of the patients do not respond to primary (chemotherapy) treatment. 20-30% van de patiënten met gevorderd ovariumcarcinoom heeft geen goede respons op de 1e keus chemotherapie die wordt gegeven.
Conditions
Interventions
Ascites drainage
One extra blood tube
Both are standard of care (the blood tube is extra)
Sponsors
Radboudumc
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Histologically confirmed ovarian, tubal or extra-ovarian peritoneal cancer - Availability of ascites - Availability of blood cells to determine gene status in normal (i.e., non-tumor) cells - Ascites collected before start of chemotherapy - No prior chemotherapy - No concomitant cancer - Age 18 years and above - Ability to undergo first line treatment (debulking surgery and chemotherapy) - Treatment to commence within 6 weeks - Written informed consent
Exclusion criteria
Exclusion criteria: - Previous chemotherapy - Previous or concurrent malignant disease except basal cell carcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development and validation of a precision medicine approach based on the analysis of drug sensitivity markers in ascites of ovarian cancer patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To compare clinical response on chemotherapy with the histopathological response seen in the tumor after neoadjuvant chemotherapy. To develop a new (histopathologic) parameter of response that is applicable in daily practice. 2. To study the immunological response in ascites of EOC patients before and after chemotherapy. To come to a better understanding of the role of the immune system in the development of ovarian cancer. | — |
Contacts
Public ContactJudith den Ouden
Radboudumc
Outcome results
None listed